1-3 of 3
Joe Stephenson, MD
Close
Sort by
Journal Articles

Results of a Phase II Open-Label Trial of Bortezomib in Patients with Multiple Myeloma Who Have Undergone High-Dose Melphalan Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation and Failed to Achieve a Complete Response

Robert M. Rifkin, MD, Gary Spitzer, MD, Andrew Greenspan, MD, John F. Schwerkoske, MD, Romeo A. Mandanas, MD, FACP, Joe Stephenson, MD, George T. Kannarkat, Feng Zhan, PhD, Lina Asmar, PhD, Roy Beveridge, MD
Journal: Blood
Blood (2008) 112 (11): 2780.
https://doi.org/10.1182/blood.V112.11.2780.2780
Published: 2008
Journal Articles

Safety, Tolerability, and Pharmacokinetic Assessment of CG53135 Administered Intravenously in Patients with Advanced (Stage 4) Cancer (Single Rising-Dose Tolerance).

Joe Stephenson, MD, Sanjay Goel, MD, Pankaj Bhargava, MD, Saroj Vadhan-Raj, MD, Vincent Annino, Thomas Hawthorne, PhD, Yuan-Di Halvorsen, PhD, William Hahne, MD
Journal: Blood
Blood (2004) 104 (11): 5030.
https://doi.org/10.1182/blood.V104.11.5030.5030
Published: 2004
Journal Articles

Phase 1 Study of Talabostat and Rituximab in Patients with Indolent Non-Hodgkin’s Lymphoma with Primary Resistance to or Progression Following Rituximab.

Ayad Al-Katib, MD, David D. Hurd, MD, Robert Raju, MD, Joe Stephenson, MD, Francis Giles, MD, Eric Haltom, Margaret J. Uprichard, PharmD
Journal: Blood
Blood (2004) 104 (11): 1403.
https://doi.org/10.1182/blood.V104.11.1403.1403
Published: 2004